transglutaminase (IgA) antibodies. Six patients were DQ2 positive.

After being diagnosed of CD and starting the GFD, SLE patients seem to improve especially the leukopenia, lymphopenia and oral aphthosis, as well as SLEDAI score (shown in attached graphics).

Conclusions SLE patients with CD diagnosis and who started a GFD, showed improvement of leukopenia, lymphopenia, oral aphthosis and even SLEDAI.

In SLE patients with recurrent oral aphthosis and/or gastrointestinal unspecific symptoms, CD should be considered, but since serological screening displays a low sensitivity, HLA testing could be helpful. Gastroscopy should be considered, with biopsy and flow cytometer in uncertain cases. Even though, further studies, especially looking for different clinical profiles and longer observational period are needed.

**P62** POLY-AUTOIMMUNITY FREQUENCY IN SLE PATIENTS FROM A TERTIARY HOSPITAL

Samuel Leal-Rodriguez, Elena Grau-Garcia, Roxana González-Mazarro, Marta De-la-Rubia-Navarro, Cristóbal Pávez-Perales, Isabel Martínez-Cordell, Carmen Nájera-Herranz, Rosa Negueruelo-Albuiach, José Eloy Oller-Rodriguez, Francisco Miguel Orza-Sanzúan, Elvia Vicens-Bernabu, Cristina Alcaraz-Escandell, Inés Cánovas-olmos, Inmaculada Chalmeta-Verdejo, Jorge Juan Fregio-Gil, Luis González-Puig, José Iovra-Cortés, José Andrés Román-Ivorra. Rheumatology Dept., Hospital Universitario y Politécnico de La Fe, Valencia, Spain

10.1136/lupus-2020-eurolupus.109

**Background/ Purpose** Poly-autoimmunity (PAI) is the presence of more than one Autoimmune Disease (AID) in one patient. The coexistence of Systemic Lupus Erythematosus (SLE) with other AIDs is a clinical challenge due to is one of the issues not yet elucidated in medical practice.

We aimed to determine PAI frequency in the context of SLE patients reported in a tertiary hospital.

**Methods** Cross-sectional observational study with systematic revision of electronic clinical records of SLE patients with other AIDs (from 2014 to 2018) was performed. Demographic, clinical and immunological data were collected.

**Results** Of 261 SLE patients, 48 (18.39%) had PAI. Mean age was 51.19 (15.35) years (93.75% were female). 2 patients from the 48 (4.16%) had PAI with three AIDs. The 75% of cases developed SLE as the first AID. The mean age at diagnosis of the first AID was 35.52 (15.33) years and mean age at diagnosis of the second AID was 43.75 (16.31) years. A mean difference of 8.31 (9.24) years between the first and second AIDs debut was observed.

The most frequent AIDs registered that go along with SLE are Antiphospholipid Syndrome (APS)(39.58%), Sjögren Syndrome (SS)(31.25%), and Rheumatoid Arthritis (RA) (16.67%). Moreover, in two cases a third AID was registered: SLE-SS-APS and SLE-APS-autoimmune-thyroiditis.

In the SLE-APS group, SLE was the AID of debut in the 89.47% of cases, instead of SLE-RA group with a 62.5%. The SLE-APS group showed a 47.37% of cases with positive antiphospholipid antibodies and 64.71% positive lupus anticoagulant. In the SLE-RA group a 71.43% and 66.67% positive rheumatoid factor and anti-CCP antibody was reported.

**Conclusions** 18.39% of patients with PAI in our group of SLE patients was observed, mostly with the SLE as the first AID developed. The most frequent association of AIDs in SLE cases were with APS, SS and RA.

**P63** ABNORMAL DISTRIBUTION OF CD27+ IGD- UNSWITCHED AND CD27+ IGD+ SWITCHED MEMORY B CELLS IN SLE PATIENTS EXPOSED TO ORGANIC SOLVENTS

1Carolina Hurtado, 2Diego Rojas-Gualdrón, 3Elisa María Vázquez-Trespalacios, 4Ricardo Pineda, 5Scott Jenks, 6Gloria Vázquez, 7Lukí Sanz. 1School of Graduate Studies and School of Medicine, CES University, Medellin, Colombia; 2School of Medicine, CES University, Medellin, Colombia; 3Group of Clinical Information, AstroMeda IPS, Medellin, Colombia; 4Dept. of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, USA; 5Grupo de inmunología celular e inmunogenética, Universidad de Antioquia, Medellin, Colombia

10.1136/lupus-2020-eurolupus.110

**Background** Some studies in animal models, support an association between occupational exposure to Organic Solvents (OS) and Systemic Lupus Erythematosus (SLE). The specific physiopathological changes that these chemicals could induce to accelerate an autoimmune response are not known. Disregulation of B cells is central in SLE, but very little is known on how OS exposure could influence it. This study aimed to examine the distribution of B cell subsets on Healthy Controls and SLE patients occupationally exposed to OS.

**Methods** 40 SLE patients who met ACR criteria and 17 Healthy Controls were recruited and classified as occupationally exposed or not to OS. Cryopreserved peripheral lymphocytes were analyzed by multiparametric Flow Cytometry using CD3, CD19, CD27, and IgD markers.

**Results** SLE patients exposed to OS had increased frequencies of CD27+ Switched Memory (SWM) cells. This change was associated with a specific OS like degreasers and ketones. Additionally, the few HC exposed to OS showed a decrease in Unswitched (USM) cells, with similar frequencies as those seen in SLE patients.

**Conclusions** Exposure to OS increased SWM cells on SLE patients and decreased USM cells on Healthy Controls. The influence of OS on SWM differentiation may be mediated through T cells. Previous reports of exposure to Trichloroethylene (a common OS), showed increased CD4+ T cell activation and secretion of INF-γ, this causes excessive T follicular helper development and germinal center formation in mice that could induce abnormalities in B cell subsets, and a similar mechanism may operate in OS exposed patients. Further research is needed to verify this hypothesis.

**P66** UTILIZATION OF GEOGRAPHIC INFORMATION SYSTEM (GIS) MAPPING TO ASSESS DISSEMINATION OF A LUPUS COMMUNITY BASED HEALTH AWARENESS MODEL

1Karen Mancera-Cuevas, 2Daniel L Erickson, 1Anh Chung, 3Courtnie Phillip, 1Candace Feldman, 2Patricia Canessa, 3Rosalind Ramsey-Goldman. 1Medicine/Rheumatology, Northwestern University, Chicago; 2Preventive Medicine, Northwestern University, Chicago; 3Division of Rheumatology, Brigham and Womans Hospital, Boston; 4Illinois Public Health Association, Springfield, USA

10.1136/lupus-2020-eurolupus.111

**Background** We used a Popular Opinion Leader (POL) model, which leverages community leaders’ social networks to disseminate health information and change norms in vulnerable communities. We established an academic-community partnerships in Chicago and Boston to increase knowledge about lupus and promote early care-seeking behaviors among African American